Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Bavituximab (Synonyms: Anti-PS MAb 3G4)

Catalog No. T77401 Copy Product Info
🥰Excellent
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth. It has anti-cancer activity and is frequently used with Paclitaxel and Carboplatin in non-small cell lung cancer studies.

Bavituximab

Copy Product Info
🥰Excellent
Catalog No. T77401
Synonyms Anti-PS MAb 3G4

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth. It has anti-cancer activity and is frequently used with Paclitaxel and Carboplatin in non-small cell lung cancer studies.

Bavituximab
Cas No. 648904-28-3
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$413-In Stock
5 mg$987-In Stock
10 mg$1,650-In Stock
25 mg$2,460-In Stock
50 mg$3,320-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:> 95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth. It has anti-cancer activity and is frequently used with Paclitaxel and Carboplatin in non-small cell lung cancer studies.
In vitro
Bavituximab binds to exposed phosphatidylserine (PS) molecules through the serum protein β2-glycoprotein 1 (β2GP1)[1], inducing antibody-dependent cellular cytotoxicity and leading to the destruction of tumor vessels[1]. Bavituximab (10 μg/mL; 48 h) binds to PS induced by 10 μM Sorafenib in HUVEC and bEnd.3 cells[2].
In vivo
Sorafenib induces anionic phospholipid exposure in a mouse tumor model, which is detected by Bavituximab (100 μg/mouse; i.v.; single dose) administered 48 hours post-Sorafenib treatment[2].
SynonymsAnti-PS MAb 3G4
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetPhosphatidylserine
Chemical Properties
Molecular Weight145.3 kDa
Cas No.648904-28-3
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storage-20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Bavituximab | purchase Bavituximab | Bavituximab cost | order Bavituximab | Bavituximab in vivo | Bavituximab in vitro | Bavituximab molecular weight